Patnaik, Mrinal M. http://orcid.org/0000-0001-6998-662X
Zeidan, Amer M.
Padron, Eric http://orcid.org/0000-0002-4707-7916
Platzbecker, Uwe http://orcid.org/0000-0003-1863-3239
Sallman, David A. http://orcid.org/0000-0003-0504-8233
DeZern, Amy E.
Bejar, Rafael
Sekeres, Mikkael http://orcid.org/0000-0003-2009-6524
Taylor, Justin http://orcid.org/0000-0003-4407-6325
Little, Richard F. http://orcid.org/0000-0002-4091-1699
Bewersdorf, Jan P.
Kim, Tae Kon. http://orcid.org/0000-0002-5182-3870
Kim, Nina http://orcid.org/0000-0002-1809-0417
Hourigan, Christopher S.
Dela Porta, Matteo G.
Stahl, Maximilian
Steensma, David
Xu, Mina L. http://orcid.org/0000-0001-9513-245X
Odenike, Olatoyosi
Carraway, Hetty http://orcid.org/0000-0001-5241-3614
Fenaux, Pierre
Nazha, Aziz
Komrokji, Rami http://orcid.org/0000-0002-1876-5269
Loghavi, Sanam http://orcid.org/0000-0001-8980-3202
Xie, Zhuoer http://orcid.org/0000-0003-1266-9804
Hasserjian, Robert http://orcid.org/0000-0002-7753-0697
Savona, Michael http://orcid.org/0000-0003-3763-5504
Bennett, John M.
Article History
Received: 27 September 2022
Revised: 26 October 2022
Accepted: 28 October 2022
First Online: 5 November 2022
Change Date: 18 November 2022
Change Type: Update
Change Details: The super title has been corrected.
Competing interests
: The first international workshop on MDS was planned by an independent scientific steering committee. The meeting was supported by unrestricted educational grants from Gilead, Novartis, BMS, Syros, Geron and Karyopharm to Magdalen Medical/VJHemOnc. The International Consortium for MDS (icMDS); a panel of international experts with a focus on preclinical and clinical MDS research including basic scientists, medical oncologist/hematologists, and pathologists convened in the 1st international workshop on MDS, which was held in Miami, FL in June 2022. This manuscript was drafted by a core group with iterative review by all authors. The meeting sponsors were not involved in the development of this manuscript. All authors developed and approved this manuscript in their personal capacity and their views do not necessarily represent/reflect that of their employers. MMP, EP, SL, UP, DS, RB are authors on WHO classification. MS, RH and OO are authors on the ICC system. RK worked with WHO on the MDS classification, but not on MDS/MPN overlap neoplasms. MMP has received research funding from Kura Oncology and Stemline Pharmaceuticals. AMZ is a Leukemia and Lymphoma Society Scholar in Clinical Research and received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Cardiff oncology, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics. AMZ participated in advisory boards, and/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Cardiff Oncology, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, and Tyme. AMZ served on clinical trial committees for Novartis, Abbvie, Gilead, BioCryst, Abbvie, ALX Oncology, Geron and Celgene/BMS. AD received consulting fees from Geron, Bristol-Myers Squibb, Novartis, Takeda, Geron, Taiho, CTI Biopharma, Gilead. RB conflicts of interest include: Aptose Biosciences - employment and equity, Gilead - data safety monitoring committees chair, Epizyme - data safety monitoring committee chair, BMS - honoraria, research funding, Takeda - research funding. RK consulted for Abbvie: Speaker Bureau, Advisory board; BMS: Research Grant, Advisory board; CTI biopharma: Speaker Bureau, Advisory board; Geron: Consultancy; Jazz: Speaker Bureau, Advisory board. Novartis: Advisory board; Pharma Essentia: Speaker Bureau, Advisory board; Servio: Speaker Bureau, Advisory board; Taiho: Advisory board. MS has participated in advisory Boards for BMS, Kurome and Novartis. JT has participated in advisory board for Kyropharm. TKK has received funding from Nextcure, that is not relevant to this manuscript. TKK is a consultant for Agenus and Immunobiome. MS consulted for Curis Oncology and Boston Consulting; served on the advisory board for Novartis, Kymera and Sierra Oncology; and participated in GME activity for Novartis, Curis Oncology, Haymarket Media and Clinical care options (CCO) DS has the following COI: Novartis (employment) and Bluebird and Arrowhead (Stock Ownership). MX participated in advisory boards and/or had a consultancy with and received honoraria from Seattle Genetics, Pure Marrow and Blueprint Medicines. PF has received honoraria and, as Groupe Francophone des Myelodysplasie’s chairperson, research support from: BMS/Celgene, Novartis, Janssen, Jazz, Abbvie. AN owns stocks in Amazon and Incyte. Employee at Incyte Pharmaceutical. SL has received research funding from Amgen and Astellas, has participated in advisory Boards for Abbvie and Guidepoint; has served as a consultant for Gerson Lehrman Group and QualWorld, and has stock ownership in Abbvie. OO has served on the advisory board of Bristol-Myers Squibb, Celgene, Novartis, Taiho and Kymera Therapeutics; serves on a DSMB for Threadwell Therapeutics and received research funding (institutional) from ABBVIE, Agios, Aprea, Astex, Astra Zeneca, Bristol Myers Squibb, Celgene, CTI, Daiichi, Incyte, Janssen, Kartos, Loxo, Novartis, NS-Pharma and Oncotherapy Sciences.